<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04467333</url>
  </required_header>
  <id_info>
    <org_study_id>PH in lung cancer registry</org_study_id>
    <nct_id>NCT04467333</nct_id>
  </id_info>
  <brief_title>Giessen Pulmonary Hypertension in Lung Cancer Registry</brief_title>
  <acronym>PHLHR</acronym>
  <official_title>Giessen Pulmonary Hypertension in Lung Cancer Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the frequency and implications of pulmonary
      hypertension in lung cancer patients. To do so, data will be collected from all lung cancer
      patients at the university hospital Giessen. All data will be analyzed for possible hints of
      pulmonary hypertension as a comorbidity in lung cancer patients. All information will be
      generated from the regular guidelines based course of treatment and there will be no
      interventions. This study will serve as a prospective register for all lung cancer patients
      treated at the university hospital Giessen.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Anticipated">January 29, 2040</completion_date>
  <primary_completion_date type="Anticipated">January 29, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Weeks</target_duration>
  <primary_outcome>
    <measure>Pulmonary function test measured via Spirometry.</measure>
    <time_frame>2 years</time_frame>
    <description>vital capacity, total lung capacity, forced expiratory volume in one second, functional vital capacity, diffusing capacity for carbon monoxide, arterial partial pressure of oxygen; all measured as % of predicted normal values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sPAP values measured via Echocardiography.</measure>
    <time_frame>2 years</time_frame>
    <description>systolic pulmonary artery pressure (sPAP) measured in millimetre of mercury (mmHg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body mass index.</measure>
    <time_frame>2 years</time_frame>
    <description>weight and height will be combined to report BMI in kg/m^2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival and Progression Free Survival measured in days.</measure>
    <time_frame>2 years</time_frame>
    <description>Overall Survival and Progression free survival in days will be determined by Kaplan-Meier Analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurements of the pulmonary artery diameter (PA) and ascending aorta (AA) diameter measured via computed tomography scan. PA and AA will be measured in millimeters.</measure>
    <time_frame>2 years</time_frame>
    <description>PA and AA will be combined to report the PA/AA quotient as indicator for pulmonary hypertension in all lung cancer patients. With a cut off value of ≥ 1 defining pulmonary hypertension.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 Minute Walk Test in meters.</measure>
    <time_frame>2 years</time_frame>
    <description>The 6 minute walk test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance in meters covered over a time of 6 minutes is used as the outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Medical Research Council Scale (mMRC).</measure>
    <time_frame>2 years</time_frame>
    <description>Scores on the mMRC reach from 0-4, with higher scores indicating greater dyspnea.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>chronic obstructive pulmonary disease assessment test (CAT).</measure>
    <time_frame>2 years</time_frame>
    <description>Scores on the CAT reach from 0-40, with higher scores indicating greater dyspnea.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Hypertension Due to Lung Diseases and Hypoxia</condition>
  <arm_group>
    <arm_group_label>All lung cancer patients</arm_group_label>
    <description>There will not be an intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>All lung cancer patients.</intervention_name>
    <description>There will be no specific interventions. All patients will receive guidelines based therapy of lung cancer and their comorbidities.</description>
    <arm_group_label>All lung cancer patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Equivalent to the average of patients with lung cancer in Germany.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with lung cancer at the University of Giessen lung Cancer Center.

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bastian Eul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>JLU Giessen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Khodr Tello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>JLU Giessen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bastian Eul, MD</last_name>
    <phone>(+49) 0641/985-42371</phone>
    <email>bastian.eul@innere.med.uni-giessen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael John Cekay, MD</last_name>
    <email>michael.cekay@innere.med.uni-giessen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital Giessen</name>
      <address>
        <city>Gießen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bastian Eul, MD</last_name>
      <email>bastian.eul@innere.med.uni-giessen.de</email>
    </contact>
    <contact_backup>
      <last_name>Michael John Cekay, MD</last_name>
      <email>michael.cekay@innere.med.uni-giessen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Khodr Tello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Pullamsetti SS, Kojonazarov B, Storn S, Gall H, Salazar Y, Wolf J, Weigert A, El-Nikhely N, Ghofrani HA, Krombach GA, Fink L, Gattenlöhner S, Rapp UR, Schermuly RT, Grimminger F, Seeger W, Savai R. Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. Sci Transl Med. 2017 Nov 15;9(416). pii: eaai9048. doi: 10.1126/scitranslmed.aai9048.</citation>
    <PMID>29141888</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

